Department of Breast Surgery, Henan Provincial People's Hospital, People's Hospital of Zhengzhou University, School of Clinical Medicine, Henan University, Zhengzhou, 450003, Henan, China.
Henan Provincial Food and Drug Evaluation and Inspection Center, Henan Food and Drug Administration, Zhengzhou, 450018, Henan, China.
Clin Transl Oncol. 2019 Aug;21(8):1085-1092. doi: 10.1007/s12094-018-02031-5. Epub 2019 Jan 10.
The prognostic value of nonsentinel lymph-node (NSLN) status in breast cancer remains unclear. This study was designed to investigate the prognostic value of NSLN status in SLN-positive breast cancer.
Retrospective 873 consecutive primary breast cancer patients from a single institution who were SLN-positive and underwent axillary lymph-node dissection (ALND) were included. Patients with incomplete clinical information or loss of follow-up were excluded. Survival analysis in patients with the same number of positive LNs and patients belonging to the same American Joint Committee on Cancer (AJCC) node (N) classification was performed to establish a proposal for incorporating the NSLN status into the breast cancer staging system.
The median follow-up was 41 months. Positive NSLN status was a significantly unfavorable factor for recurrence-free survival (RFS) (HR: 4.31, P < 0.001) and distant recurrence-free survival (DRFS) (HR: 3.62, P < 0.001). The survival of patients with one positive SLN and one positive NSLN (N = 97) was significantly worse than that of patients with two positive SLNs (N = 68; RFS, P = 0.011; DRFS, P = 0.027). Positive NSLN status was a significantly unfavorable factor affecting survival in patients with the AJCC N1 classification (N = 806; RFS, HR: 2.85, P = 0.002; DRFS, HR: 2.81, P = 0.004). No significant difference in survival was found between LN-negative (N = 361) and NSLN-negative AJCC N1 classification (N = 363) patients.
Positive NSLN status has an independent prognostic value in breast cancer patients with 1-3 positive LNs, and the NSLN status should be incorporated into the breast cancer staging system.
非前哨淋巴结(NSLN)状态在乳腺癌中的预后价值仍不清楚。本研究旨在探讨前哨淋巴结阳性乳腺癌中 NSLN 状态的预后价值。
回顾性分析了来自单一机构的 873 例前哨淋巴结阳性并接受腋窝淋巴结清扫术(ALND)的原发性乳腺癌患者。排除临床资料不完整或失访的患者。对具有相同阳性淋巴结数量和相同美国癌症联合委员会(AJCC)淋巴结(N)分类的患者进行生存分析,以提出将 NSLN 状态纳入乳腺癌分期系统的建议。
中位随访时间为 41 个月。NSLN 阳性是无复发生存(RFS)(HR:4.31,P<0.001)和远处无复发生存(DRFS)(HR:3.62,P<0.001)的显著不利因素。1 个前哨淋巴结和 1 个 NSLN 阳性(N=97)患者的生存明显差于 2 个前哨淋巴结阳性(N=68)患者(RFS,P=0.011;DRFS,P=0.027)。NSLN 阳性是 AJCC N1 分类(N=806)患者生存的显著不利因素(RFS,HR:2.85,P=0.002;DRFS,HR:2.81,P=0.004)。阴性淋巴结(N=361)和 NSLN 阴性 AJCC N1 分类(N=363)患者的生存无显著差异。
NSLN 阳性在前哨淋巴结 1-3 阳性的乳腺癌患者中有独立的预后价值,NSLN 状态应纳入乳腺癌分期系统。